HOUSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Powell Industries, Inc. (NASDAQ: POWL), a leading supplier of custom-engineered solutions for the management, control and distribution of electrical energy, today announced results for the third quarter of fiscal 2025 ended June 30, 2025. All comparisons are to the third quarter of fiscal 2024, unless otherwise noted. Third Quarter Key Financial and Strategic Highlights: Revenues of $286 million were essentially unchanged;Gross profit of $88 million, or 30.7% of r ...

Financial Performance - Par Pacific reported net income of $59.5 million, or $1.17 per diluted share, for Q2 2025, compared to $18.6 million, or $0.32 per diluted share, in Q2 2024 [2][10] - Adjusted Net Income for Q2 2025 was $78.3 million, up from $28.5 million in Q2 2024 [2] - Adjusted EBITDA for Q2 2025 was $137.8 million, a 69% increase from $81.6 million in Q2 2024 [2] Operational Highlights - The Refining segment reported operating income of $81.3 million in Q2 2025, compared to $41.2 million in Q2 2024 [4] - Adjusted Gross Margin for the Refining segment was $231.8 million in Q2 2025, up from $176.6 million in Q2 2024 [4] - Hawaii refinery achieved record throughput of 88 thousand barrels per day (Mbpd) in Q2 2025, compared to 81 Mbpd in Q2 2024 [10] Segment Performance - Hawaii Index averaged $8.57 per barrel in Q2 2025, compared to $7.41 per barrel in Q2 2024 [5][29] - Montana Index averaged $20.29 per barrel in Q2 2025, up from $19.15 per barrel in Q2 2024 [7][29] - Washington Index averaged $15.37 per barrel in Q2 2025, compared to $7.25 per barrel in Q2 2024 [9][29] - Wyoming Index averaged $21.41 per barrel in Q2 2025, up from $17.45 per barrel in Q2 2024 [12][29] Strategic Initiatives - Successful completion of the Montana turnaround and progress on the Hawaii SAF project [3] - Announcement of the Hawaii Renewables joint venture with expected cash proceeds of $100 million [10] - Opportunistic reduction of shares outstanding by 3% during the quarter, totaling 8% year-to-date [3] Liquidity and Capital Management - Net cash provided by operations totaled $133.6 million for Q2 2025, including working capital inflows of $122.9 million [17] - Total liquidity increased by 23% during the quarter to $647.0 million at June 30, 2025 [18] - Company repurchased $28 million of common stock at an average price of $17.36 per share during Q2 2025 [10][18]

Core Viewpoint - Dyadic International, Inc. is set to report its financial results for the second quarter of 2025 and will host a corporate update conference call on August 13, 2025 [1] Group 1: Financial Reporting - The company will announce its financial results for Q2 2025 on August 13, 2025 [1] - A conference call will take place at 5:00 p.m. Eastern Time on the same day [2] - Dial-in numbers for the conference call are provided, including a toll-free option and an international number [2] Group 2: Company Overview - Dyadic is a global biotechnology company focused on scalable production of high-value, precision-engineered functional input proteins [1][4] - The company utilizes proprietary gene expression platforms for applications in life sciences, food and nutrition, and industrial biotechnology [1][4] - Dyadic's C1 and Dapibus™ expression systems support flexible and cost-effective manufacturing, forming the basis of its commercial and partnered programs [4]

Core Insights - Cipher Mining Inc. reported its unaudited production and operations update for July 2025, highlighting significant metrics in bitcoin mining and operational efficiency [1] Production Metrics - The company mined approximately 214 BTC in July 2025, with 52 BTC sold during the month, resulting in a total holding of around 1,219 BTC at month-end [2][4] - Cipher deployed 115,000 mining rigs, achieving a month-end operating hashrate of 20.4 EH/s and a fleet efficiency of 19.2 J/TH [2] Financial Performance - The estimated power sales for July were equivalent to approximately 6 BTC, based on the month-end bitcoin price of $115,637, along with an additional 21 BTC mined at joint venture data centers representing Cipher's ownership [2][6] Operational Developments - The Black Pearl Phase I project began contributing significantly to production, accounting for about 24% of the total bitcoin mined in July, with expectations for increased contributions in the coming months as the project scales [3][5] - A business update is scheduled for the earnings call on August 7, 2025, where further insights into the company's operations will be shared [3]

Core Insights - Merus N.V. announced promising clinical trial results for petosemtamab in combination with pembrolizumab, showing a 63% response rate among 43 evaluable patients and a 79% overall survival rate at 12 months in a phase 2 trial for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) [1][3][6] Clinical Trials and Efficacy - The ongoing LiGeR-HN1 and LiGeR-HN2 phase 3 trials are expected to be substantially enrolled by the end of 2025, with potential interim readouts in 2026 [4][5] - Initial clinical data for petosemtamab in metastatic colorectal cancer (mCRC) is anticipated in the second half of 2025 [2][8] Financial Overview - The company completed a public offering raising $345 million in gross proceeds, which, along with existing cash and marketable securities, is expected to fund operations at least into 2028 [17][18] - Total revenue for Q2 2025 increased by $1.5 million compared to Q2 2024, driven by collaboration revenues [19] - Research and development expenses for Q2 2025 rose by $44.8 million, primarily due to increased clinical trial support related to petosemtamab [20] Collaborations and Licensing - Merus has established collaborations with several companies, including Incyte, Eli Lilly, Gilead Sciences, and Biohaven, focusing on the development of bispecific antibodies and novel therapies [11][12][15][16] - The company has licensed BIZENGRI for commercialization in the U.S. for specific cancer types, enhancing its market presence [9] Cash Position and Runway - As of June 30, 2025, Merus reported $892 million in cash, cash equivalents, and marketable securities, providing a strong financial position to support ongoing and future clinical trials [18]

BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. “Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closel ...

Core Insights - OrthoPediatrics Corp. reported a record revenue of $61.1 million for Q2 2025, marking a 16% increase year-over-year, with adjusted EBITDA rising by 58% to $4.1 million [1][4][8] Financial Performance - Total revenue for Q2 2025 was $61.1 million, up from $52.8 million in Q2 2024, driven by strong growth in Scoliosis, Trauma, and OPSB products [4][8] - U.S. revenue reached $48.1 million, a 17% increase from $41.2 million in the same quarter last year, accounting for 79% of total revenue [4][8] - International revenue was $12.9 million, a 12% increase from $11.6 million year-over-year [4][8] - Trauma and Deformity revenue grew by 10% to $41.7 million, while Scoliosis revenue surged by 35% to $18.5 million [5][8] - Gross profit for Q2 2025 was $44.0 million, an 8% increase from $40.8 million in Q2 2024, with a gross profit margin of 72% [6][8] Operating Expenses - Total operating expenses increased by 18% to $54.7 million, primarily due to restructuring charges and increased personnel costs [7][8] - Sales and marketing expenses rose by 15% to $19.1 million, driven by higher sales commissions [9][8] - General and administrative expenses increased by 11% to $30.4 million, reflecting higher non-cash stock compensation and additional personnel [10][8] Net Loss and Cash Flow - The net loss for Q2 2025 was $7.1 million, compared to a loss of $6.0 million in Q2 2024, with a GAAP diluted loss per share of ($0.30) [12][8] - Non-GAAP diluted loss per share improved to ($0.11) from ($0.23) year-over-year [12][8] - Cash, cash equivalents, and short-term investments totaled $72.2 million as of June 30, 2025, up from $70.8 million at the end of 2024 [13][8] Business Expansion - The company expanded its OrthoPediatrics Specialty Bracing Division (OPSB) with new clinics and entered two new territories, including its first international operation in Ireland [8] - Full-year 2025 revenue guidance was raised to a range of $237.0 million to $242.0 million, indicating a growth of 16% to 18% compared to the previous year [14][8]

Core Viewpoint - BlackLine, Inc. announces a leadership transition where Therese Tucker will step down as Co-CEO to focus on her role as Founder, effective October 1, 2025, while Owen Ryan will continue as CEO [1][2][3] Leadership Transition - Therese Tucker will remain involved with BlackLine as a member of the executive team, focusing on supporting major customers and enhancing product development [2][3] - Owen Ryan, who has served as Co-CEO and Chairman, will take on the role of CEO [1][3] - David Henshall has been appointed as Lead Independent Director, succeeding Tom Unterman [3][4] Strategic Enhancements - The Board of Directors has made strategic enhancements, including the addition of former CEOs Sam Balaji and Greg Hughes, to support BlackLine's long-term strategy [4] - The leadership transition is seen as a pivotal moment for BlackLine's evolution, with a focus on innovation and execution [3] Company Overview - BlackLine is positioned as a future-ready platform for the Office of the CFO, driving digital finance transformation through efficient financial operations [5][6] - The platform addresses critical processes such as record-to-report and invoice-to-cash, providing real-time insights and automation [6] - BlackLine serves over 4,400 customers across various industries, emphasizing its commitment to innovation and security [6]

Core Insights - Clover Health Investments, Corp. reported strong financial results for Q2 2025, highlighting significant membership and revenue growth, along with sustained profitability metrics [2][3][4] - The company's technology-first model is credited for driving better care management and improved health outcomes for members, particularly in Medicare Advantage plans [3][20] - Clover Health updated its full-year 2025 guidance, maintaining insurance revenue expectations while improving projections for adjusted SG&A and membership growth [10][4] Financial Performance - Q2 2025 insurance revenue reached $469.8 million, a 34.3% increase from $349.9 million in Q2 2024 [4][3] - Total revenues for Q2 2025 were $477.6 million, up 34% year-over-year [4][3] - Average Medicare Advantage membership increased by 31.8% year-over-year to 105,494 [4][3] - Adjusted net income from continuing operations was $16.7 million, down 53.5% from $35.9 million in Q2 2024 [4][3] - Adjusted EBITDA for Q2 2025 was $17.1 million, a decrease of 52.8% compared to $36.2 million in Q2 2024 [4][3] Membership and Revenue Guidance - The company expects average Medicare Advantage membership to be between 104,000 and 108,000 for the full year 2025, representing a 32% growth year-over-year at the midpoint [4][10] - Insurance revenue guidance for 2025 is maintained at $1.800 billion to $1.875 billion, indicating a 37% growth year-over-year at the midpoint [10][4] - Adjusted SG&A is projected to be between $335 million and $345 million, improving as a percentage of total revenues to 18% - 19% [10][4] Operational Metrics - The Insurance Benefits Expense Ratio (BER) for Q2 2025 was 88.4%, up from 76.1% in Q2 2024 [4][3] - The company reported a net loss from continuing operations of $10.6 million for Q2 2025, compared to a net income of $7.2 million in Q2 2024 [4][3] - Total cash, cash equivalents, and investments decreased by 19.4% to $389.3 million from $482.8 million year-over-year [4][3]

Core Insights - Sow Good Inc. has appointed Jeff Rubin to its Board of Directors, effective August 1, 2025, to fill a vacancy [1] - Jeff Rubin has 35 years of experience in the confectionery industry, having founded IT'SUGAR and co-founded Dylan's Candy Bar and FAO Schweetz [2] - The CEO of Sow Good, Claudia Goldfarb, expressed excitement about Rubin's appointment, highlighting his extensive background and prior advisory work with the company [3] Company Overview - Sow Good Inc. is a U.S.-based manufacturer specializing in freeze dried candy and snacks, focusing on innovative and flavorful products [3] - The company utilizes proprietary freeze-drying technology and a specialized manufacturing facility to create a new category of candy known as freeze dried candy [3] - Sow Good is committed to growth through its core pillars: innovation, scalability, manufacturing excellence, meaningful employment opportunities, and food quality standards [3]